Insider Selling: AstraZeneca (LON:AZN) Insider Sells 9,563 Shares of Stock

Key Points

• Aradhana Sarin, an insider at AstraZeneca PLC, sold 9,563 shares of the company's stock for a total value of approximately £1.1 million on August 14th.
• AstraZeneca's stock saw a mild increase of 1.3% on the trading day following the sale, reaching a price of £117.38.
• Several analysts have issued mixed ratings for AstraZeneca, with target prices set between £110 and £135 depending on the firm.

AstraZeneca PLC (LON:AZN - Get Free Report) insider Aradhana Sarin sold 9,563 shares of AstraZeneca stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of £115.12, for a total transaction of £1,100,892.56.

AstraZeneca Stock Down 0.7%

LON AZN traded down GBX 84.85 during trading on Friday, reaching £119.63. The company's stock had a trading volume of 1,000,986 shares, compared to its average volume of 10,376,260. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The stock has a market capitalization of £230.17 billion, a PE ratio of 32.79, a PEG ratio of 0.86 and a beta of 0.17. The business has a 50-day moving average price of £108.06 and a 200-day moving average price of £109.18. AstraZeneca PLC has a 1-year low of GBX 9,573.51 and a 1-year high of £133.88.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on AZN. Berenberg Bank reiterated a "buy" rating and issued a GBX 140 target price on shares of AstraZeneca in a research note on Friday, May 16th. Shore Capital reaffirmed a "buy" rating and set a £135 target price on shares of AstraZeneca in a research report on Tuesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a £110 target price on shares of AstraZeneca in a research report on Wednesday, July 30th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, AstraZeneca has a consensus rating of "Moderate Buy" and a consensus price target of GBX 9,660.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.